| Product Name | HA ELISA kit (General species) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Hyaluronic Acid (HA). No significant cross-reactivity or interference between Hyaluronic Acid (HA) and analogues was observed. |
| Synonyms | Hyaluronan; Hyaluronate |
| Method | Competitive |
| Detection Range | 4.94-400ng/mL |
| Sensitivity | 1.71ng/mL |
| Target | HA |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Hyaluronic Acid (HA). No significant cross-reactivity or interference between Hyaluronic Acid (HA) and analogues was observed. |
| Sample Types | Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 50uL standard or sample to each well. And then add 50uL prepared Detection Reagent A immediately. Shake and mix.Incubate 1 hour at 37℃; 3.Aspirate and wash 3 times; 4.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 5.Aspirate and wash 5 times; 6.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 7.Add 50uL Stop Solution.Read at 450 nm immediately. |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Hemorrhagic Fever Caused by a Novel Bunyavirus in China: Pathogenesis and Correlates of Fatal Outcome;Alveolar fluid in acute respiratory distress syndrome promotes fibroblast migration: Role of platelet-derived growth factor pathway*;Age effects on extracellular matrix production of vocal fold scar fibroblasts in rats;Vocal Fold Fibroblast Response to Growth Factor Treatment is Age Dependent: Results From an In Vitro Study;Resveratrol inhibits ovarian cancer cell adhesion to peritoneal mesothelium in vitro by modulating the production of α5β1 integrins and hyaluronic acid;Establishing principles of macromolecular crowding for in vitro fibrosis research of the vocal fold lamina propria;Pituitary tumor transforming gene as a novel regulatory factor of liver fibrosis;Camel Milk: Potential Utility as an Adjunctive Therapy to Peg-IFN/RBV in HCV-5 Infected Patients in Egypt;Study of Some Serum Biochemical Markers of Liver Fibrosis in Patients with Chronic HCV;A putative Chondroprotective role for IL-1β and MPO in herbal treatment of experimental osteoarthritis;Polycomb group proteins: Novel molecules associated with ultraviolet A-induced photoaging of human skin.;The effect of aerobic walking and lower body resistance exercise on serum COMP and hyaluronan, in both males and females;Evaluation of antifibrotic effects of coffee and cocoa extracts in rats with thioacetamide-induced fibrosis;Selected elements of extracellular matrix of the skin in diabetes and insulin resistance;Betulin attenuated liver damage by prevention of hepatic mitochondrial dysfunction in rats with alcoholic steatohepatitis;Damage-Associated Molecular Patterns and Th-Cell-Related Cytokines Released after Progressive Effort;An exploratory study to investigate the association between age, physical activity, femoral trochlear cartilage thickness and biomarkers of tissue metabolism in?¡;Trimethylamine N‐oxide exacerbates acetaminophen‐induced liver injury by interfering with macrophage‐mediated liver regeneration;Comparative studies on the effect of pig adipose-derived stem cells (pASCs) preconditioned with hypoxia or normoxia on skin wound healing in mice;Bicyclol ameliorates advanced liver diseases in murine models via inhibiting the IL-6/STAT3 signaling pathway;Novel multifunctional delivery system for chondrocytes and articular cartilage based on carbon quantum dots; |
| Supplier | Cloud Clone |
PROTOCOLS:
CEA182Ge All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
